Rate Video

GU Cancers 2019 | Concordance of different PD-L1 assays: expression in bladder and kidney cancer

Tian Zhang • 15 Feb 2019

GU Cancers 2019

Bladder Cancer Genitourinary Cancer Kidney Cancer Checkpoint Inhibitors

Tian Zhang, MD, of Duke Cancer Center, Durham, NC, discusses work being presented at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, on the comparability of different PD-L1 assays for both bladder and kidney cancer.

Nivolumab with ipilimumab for mRCC

Tian Zhang • 13 Feb 2020

Identifying predictive markers for checkpoint inhibitor response in kidney cancer

Characterization of circulating immune cells in metastatic urothelial cancer following treatment

Related Videos

Updates on MRx0518 + pembro in patients with resistance to therapy

Alex Stevenson • 27 Nov 2020

IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC

Aris Bamias • 23 Nov 2020

Treatment options for mUC following chemo-immunotherapy failure

Aris Bamias • 23 Nov 2020

Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?

Arlene Siefker-Radtke • 14 Oct 2020